TANTUM ROSA

Poland

The medicinal product is used for the local treatment of inflammatory symptoms, such as pain, burning, itching, redness, discharge, and swelling in the area of the external genitalia and the vagina. It also helps to relieve vulvar discomfort during the postpartum period and is used for prophylaxis before and after gynecological surgeries.

Brand name TANTUM ROSA
Dosage form powder for preparation of vaginal solution
Active substance / Dosage
Prescription type Over-the-counter
ATC code
Registration number 100065597
TANTUM ROSA powder for preparation of vaginal solution

Frequently asked questions

How to use Tantum Rosa?

Dissolve 1 sachet in 0.5 liters of boiled and cooled water immediately before use. Depending on the severity of the symptoms and the type of discomfort, 1 to 2 sachets per day may be used (e.g., morning and evening). A new solution should be prepared every time for vaginal douching or washing the perineal and vulvar areas.

When not to use the medicinal product?

Do not use the medicinal product if you are allergic to the active substance or any of the other ingredients. You should also consult a doctor before use if you are pregnant or breastfeeding – during pregnancy, the medicine should only be used if absolutely necessary and upon medical advice.

What are the possible side effects of Tantum Rosa?

Very rarely, the following may occur: a burning sensation in the vaginal mucosa, urticaria, or a photoallergic rash. If any adverse effects occur, inform your doctor, pharmacist, or nurse.

Does the medicinal product interact with other medicines?

No interactions between this medicinal product and other preparations are known; however, you should inform a specialist about all medicines you are currently taking or planning to take.

How long can the medicine be used independently?

In the case of self-treatment, the medicine should not be used continuously for longer than 7 days. To achieve improvement, treatment should last at least 3 days. If there is no improvement after 7 days or if the condition worsens, you should contact a doctor.

Instructions for use

Package leaflet: Information for the user

TANTUM ROSA
Benzydamini hydrochloridum
53.2 mg/g, powder for preparation of a vaginal solution
Please read the entire leaflet carefully before using the medicine, as it contains
important information for the patient.
This medicine should always be used according to the instructions provided in the patient leaflet or as directed by a physician, pharmacist, or nurse.

  • Keep this leaflet for future reference.
  • Consult your pharmacist if you need advice or additional information.
  • If any adverse reactions occur, including any possible side effects not listed in this leaflet, inform your doctor, pharmacist, or nurse. See section 4.
  • If symptoms do not improve or worsen after 7 days of treatment, consult your doctor.

Table of contents:

  1. What Tantum Rosa is and what it is used for
  2. Important information before using Tantum Rosa
  3. How to use Tantum Rosa
  4. Possible side effects
  5. How to store Tantum Rosa
  6. Contents of the pack and other information

1. What Tantum Rosa is and what it is used for

Tantum Rosa contains the active substance benzydamine, which belongs to the group of non-steroidal anti-inflammatory drugs (NSAIDs).
Benzydamine has anti-inflammatory and analgesic properties and acts locally as a local anesthetic and antiseptic. The drug is well absorbed locally, achieving high concentrations in tissues affected by inflammation. The drug is generally well tolerated. It is used for local treatment of inflammatory symptoms.
Tantum Rosa is administered vaginally and applied to the mucous membranes of the external genital organs.
It is used to treat discomfort and symptoms such as pain, burning, itching, redness, discharge, and swelling in the area of the external genital organs and vagina.
These symptoms occur as a result of inflammation of the vulva and vagina (vulvovaginitis), cervicitis of various origins (e.g. infections, mechanical irritation), including after chemotherapy or radiotherapy. The drug is also used for pre- and postoperative prophylaxis in gynecology, as well as for relief of vulvar discomfort during the postpartum period.

2. Important information before using Tantum Rosa

When not to use Tantum Rosa
If the patient is allergic to the active substance or to any of the other ingredients of this
medicine (listed in section 6).

Warnings and precautions
Before starting to use Tantum Rosa, consult a doctor, pharmacist, or nurse.
The use, especially prolonged, of locally acting medicines may cause an allergic reaction. In such a case, Tantum Rosa should be discontinued and the patient should consult a doctor, who will recommend appropriate management.
Tantum Rosa is intended for vaginal use and for application on the mucous membrane of the external genital organs. It must not be taken orally.

Tantum Rosa and other medicines
Inform your doctor or pharmacist about all medicines currently used, recently used, or planned to be used.
No interactions of Tantum Rosa with other medicines are known.

Pregnancy and breastfeeding
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or is planning to become pregnant, she should consult a doctor or pharmacist before using this medicine.
Tantum Rosa should not be used during pregnancy unless absolutely necessary and recommended by a doctor. If use is necessary, the lowest possible dose for the shortest possible duration should be used.
Unless otherwise directed by a doctor, the medicine should be used according to the recommendations provided in the leaflet.

Driving and operating machinery
This medicine does not affect the ability to drive or operate machinery.

3. How to use Tantum Rosa

This medicine should always be used as described in the patient information leaflet or as directed by a doctor,
pharmacist, or nurse. If in doubt, consult a doctor, pharmacist, or nurse.
The recommended dose is 1 to 2 sachets per day, depending on the severity of symptoms.
Dissolve the contents of one sachet in 0.5 litres of boiled and cooled water, immediately before use.
Always prepare a fresh solution from one sachet each time (e.g. in the morning and evening).
Treatment of discomfort and symptoms of inflammation of the external genital organs (perineal area
and vulva) associated with vaginitis and/or cervicitis: irrigate the vagina with the solution prepared from one sachet 1 to 2 times daily, unless otherwise directed by a physician.
Treatment of discomfort and symptoms of inflammation of the external genital organs (perineal area
and vulva) and postpartum perineal discomfort: wash the perineal and vulvar areas with the solution prepared from one sachet 1 to 2 times daily.
Pre- and postoperative prophylaxis in gynaecology: the physician will determine the appropriate use of the medicine.
If self-treating, do not use the medicine continuously for longer than 7 days without consulting a doctor, who will decide whether treatment should be prolonged.
To achieve improvement, treatment should not last less than 3 days.
For proper and safe vaginal irrigation (douching), read the instructions for use provided with the intimate hygiene irrigator, available in pharmacies without a prescription.
Use of a higher than recommended dose of Tantum Rosa
Overdose is unlikely due to the low concentration of the active substance in the medicine and its local route of administration. No cases of overdose have been observed to date.
If the medicine is accidentally swallowed, contact a doctor or pharmacist immediately.
If you have any further doubts regarding the use of this medicine, consult a doctor, pharmacist, or nurse.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everybody gets them.
Very rare adverse effects (occur in less than 1 person in 10,000):
sensation of burning of the vaginal mucosa, photoallergic rash, urticaria.
Reporting of adverse effects
If any adverse effects occur, including any adverse effects not listed
in this leaflet, inform your doctor, pharmacist or nurse. Adverse effects
can be reported directly to the Department of Monitoring Adverse Effects of Medicinal Products
of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products,
Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301,
fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Adverse effects can also be reported to the marketing authorisation holder.
Reporting adverse effects helps to provide more information on the safety of the medicine.

5. How to store Tantum Rosa

Keep this medicine out of sight and reach of children.
No special precautions for storage are required.
Do not use this medicine after the expiry date stated on the packaging.
The expiry date refers to the last day of the stated month.
Medicines must not be disposed of via wastewater or household waste.
Ask your pharmacist how to dispose of medicines no longer required.
This will help protect the environment.

6. Contents of the pack and other information

What Tantum Rosa contains
The active substance in Tantum Rosa is benzydamine hydrochloride.
Each sachet (9.4 g) contains 500 mg of benzydamine hydrochloride.
The other excipients are: sodium chloride, povidone, p-toluenesulfonate of trimethylammonium acetate.

What Tantum Rosa looks like and contents of the pack
Tantum Rosa is a powder which must be dissolved in water to prepare a solution.
The immediate packaging is a paper-polypropylene sachet containing 9.4 g of powder. The outer carton contains 6 or 10 sachets.

Marketing Authorisation Holder
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Viale Amelia 70, 00181 Rome, Italy

Manufacturer
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Via Vecchia del Pinocchio 22
60131 Ancona, Italy
Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Via Grignano, 43
24041 Brembate BG, Italy

Representative of the Marketing Authorisation Holder
Angelini Pharma Polska Sp. z o.o.
Aleje Jerozolimskie 181B
02-222 Warsaw
Tel.: (22) 70 28 200
E-mail: [email protected]

The original data is available in the language of the country of manufacture.

Data source: Register of Medicinal Products of Poland (URPL)

Data last verified: September 01, 2026